Hydroxyurea and sickle cell anemia: effect on quality of life

Affordable Access

Hydroxyurea and sickle cell anemia: effect on quality of life

BioMed Central
Publication Date
Aug 31, 2006
  • Medicine


1477-7525-4-59.fm ral Health and Quality of Life Outcomes ss BioMed Cent Open AcceResearch Hydroxyurea and sickle cell anemia: effect on quality of life Samir K Ballas*1, Franca B Barton2, Myron A Waclawiw3, Paul Swerdlow4, James R Eckman5, Charles H Pegelow6, Mabel Koshy7, Bruce A Barton2 and Duane R Bonds3 Address: 1Cardeza Foundation, Department of Medicine, Jefferson Medical College, Philadelphia PA, USA, 2Maryland Medical Research Institute, Baltimore MD, USA, 3National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda MD, USA, 4Wayne State University Detroit MI, USA, 5Emory University, Atlanta GA, USA, 6University of Miami, Coral Gables FL, USA and 7University of Illinois at Chicago Hospital, Chicago IL, USA Email: Samir K Ballas* - [email protected]; Franca B Barton - [email protected]; Myron A Waclawiw - [email protected]; Paul Swerdlow - [email protected]; James R Eckman - [email protected]; Charles H Pegelow - [email protected]; Mabel Koshy - [email protected]; Bruce A Barton - [email protected]; Duane R Bonds - [email protected] * Corresponding author Abstract Background: The Multicenter Study of Hydroxyurea (HU) in Sickle Cell Anemia (MSH) previously showed that daily oral HU reduces painful sickle cell (SS) crises by 50% in patients with moderate to severe disease. The morbidity associated with this disease is known to have serious negative impact on the overall quality of life(QOL) of affected individuals. Methods: The data in this report were collected from the 299 patients enrolled in the MSH. Health quality of llife (HQOL) measures were assessed in the MSH as a secondary endpoint to determine if the clinical benefit of HU could translate into a measurable benefit perceptible to the patients. HQOL was assessed with the Profile of Mood States, the Health Status Short Form 36 (SF-36), including 4-week pain recall, and the Ladder of Life, self-administered twice 2-weeks apart pre-treatment and every

Report this publication


Seen <100 times